What is the evidence for macrolide therapy in chronic rhinosinusitis?
| Autor: | Marina Neves Cavada, Jessica W. Grayson, Raymond Sacks |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class Chronic rhinosinusitis Anti-Inflammatory Agents 03 medical and health sciences 0302 clinical medicine Nasal Polyps Internal medicine medicine Eosinophilia Humans Immunologic Factors In patient Sinusitis 030223 otorhinolaryngology Glucocorticoids Rhinitis business.industry Patient Selection medicine.disease Eosinophils Chronic disease Otorhinolaryngology Corticosteroid therapy 030220 oncology & carcinogenesis Chronic Disease Corticosteroid Surgery Macrolides medicine.symptom business |
| Zdroj: | Current opinion in otolaryngologyhead and neck surgery. 28(1) |
| ISSN: | 1531-6998 |
| Popis: | Purpose of review To assess the most recent evidence for macrolide therapy in chronic rhinosinusitis (CRS). Recent findings Macrolides play a significant role in a select group of patients with CRS. Low-serum and tissue eosinophilia in patients who do not respond to corticosteroid therapy appeared to be an effective predictor of a CRS phenotype suitable for a trial of long-term macrolide therapy. Therapies using half a dose for longer than 12 weeks have noted good outcomes. Summary The anti-inflammatory and immunomodulatory effects of macrolides have been demonstrated in several studies. Macrolides have shown an important role in patients who are nonresponsive to corticosteroid therapies, therefore patient selection is key. Previous inconsistencies in results may be due to poor patient selection. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|